Phase 3Completed

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2 (MENDEL-2)

A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less

Sponsor
Amgen (Industry)
Enrollment
615 enrolled
Conditions
Hyperlipidemia
Interventions
Evolocumab; Ezetimibe; Placebo to Evolocumab; Placebo to Ezetimibe
Ages
adults, older adults
Registry
NCT01763827

Full record on ClinicalTrials.gov

From the registry

The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.

Primary outcomes

  • Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12
  • Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12

History

  1. Last registry update

  2. Results first posted

  3. Study completion

  4. Primary completion

  5. Started

  6. Registered